Pfizer, Novartis ink respiratory deal

Pfizer has inked a deal to market Novartis's chronic obstructive pulmonary disease drug Seebri Breezhaler (glycopyrronium bromide) and the Ultimo Breezhaler (indacaterol/glycopyrronium bromide) in Great Britain. Pfizer said in a statement that the country's National Health Service estimates around three million residents have COPD, one of the most common respiratory diseases.

The category has gotten a significant amount of attention of late, such as GlaxoSmithKline's efforts to shore up its Ellipta franchise and AstraZeneca's recent Almirall purchase to beef up its respiratory portfolio.

You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.